TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Cognitive Group Treatment for Borderline Outpatients
Brief Summary: This study will expose patients to either a Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) to determine the more effective therapy for treating borderline personality disorder.


Options:
A: Inclusion Criteria:

* Borderline Personality Disorder
B: Inclusion Criteria:

1. Be aged over 16 years (parental consent is not needed; The British Psychological Society, 2008)
2. Be comfortable with and have access to email and the internet for completing study measures
3. Be currently under or receiving support form clinical/health service including NHS, 3rd sector, or University health services
4. Following DSM-V (American Psychiatric Association, 2013), have had five or more instances of NSSI in the past year:

   • NSSI methods are operationalised to include cutting, burning, biting, or scratching oneself, as well as head-banging or self-poisoning.
5. Have an adequate English language ability to understand study materials
6. Be deemed capable of providing informed consent by their clinical team.

Exclusion Criteria:

1. Be currently receiving any other psychological therapy (e.g. including but not limited to CBT and/or DBT), and will not have received psychological therapies in the last one month.
2. Have previously received any CAT
3. Have been diagnosed with Learning Disability or Autistic Spectrum Disorder as judged by clinical team - since the intervention has not been developed for this population
4. Be currently judged at high risk of suicidal behaviour (although if participants were keen to be involved, they could be considered when their mental health has improved).
5. Have been hospitalised as a result of self-harm in the past month
C: Inclusion Criteria:

* Participant is male;
* Participant is 18 years of age or older;
* Participant has presented via Emergency Department to The Ottawa Hospital General and Civic Campuses with intentional self-harm;
* Participant is willing to return to the The Ottawa Hospital General Campus for follow-up appointments;
* Participant is willing to consent to participate in the study.

Exclusion Criteria:

* Participant is unable to read or understand English;
* Participant has cognitive impairments that render them incapable of using a smart phone;
* Participant does not have a smart phone and/or a smart phone with a data plan;
* Participants who in the opinion of the investigator will be unlikely to commit to a three month long study.
D: Inclusion Criteria:

* Female
* Ages 18 to 30
* Meets criteria for Borderline Personality Disorder
* Intelligence Quotient must be 71 or higher

Exclusion Criteria:

* Males
* Schizophrenia
* Schizoaffective Disorder
* Bipolar I
* Serious Substance Use Disorder
* Subjects cannot be in treatment at baseline

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Cognitive Group Treatment for Borderline Outpatients
Brief Summary: This study will expose patients to either a Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) to determine the more effective therapy for treating borderline personality disorder.


Options:
A: Inclusion Criteria:

* Borderline Personality Disorder
B: Inclusion Criteria:

* Man or woman older than 18 years old
* Right-handed
* Signed Informed Consent form
* Subject affiliated to or beneficiary from a French social security regime
* Inpatient or outpatient at the Adult Psychiatry Service
* Diagnosis of Borderline Personality Disorder according to the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and confirmation by the Structured Clinical Interview for DSM Disorders (SCID-II)
* Absence of addictive comorbidities (except: tobacco, tea, coffee)
* Absence of severe progressive neurologic and/or somatic pathologies (specially tumors, degenerative diseases)

Exclusion Criteria:

* Younger than 18 years old
* Left-handed
* Subject under measure of protection or guardianship of justice
* Presence of psychiatric comorbidities (chronic psychosis, Bipolar Disorder)
* Subject beneficiary from a legal protection regime
* Subject unlikely to cooperate or low cooperation stated by investigator
* Subject not covered by social security
* Pregnant woman
* Subject being in the exclusion period of another study or provided for by the "National Volunteer File"
C: Inclusion Criteria:

* Meets DSM-IV criteria for Borderline Personality Disorder.
* Has had at least 2 self-harm episodes (either suicidal or non-suicidal) in the past 5 years, including at least 1 in the past 8 weeks.
* Proficient in English
* Provides informed consent to participate in the study.
* Absence of 8 or more standard weeks of DBT in the past year (individual and group therapy components).
* has had either Ontario Health Insurance Plan (OHIP) coverage or BC Medical Services Plan (MSP) health insurance for 1 year or more
* Absence of a pending criminal court case or charges.
* Has been a resident of Ontario or British Columbia for all of the past 12 months, at least.
* Lives in the Greater Toronto Area/Greater Vancouver Area

Exclusion Criteria:

* Meets the DSM-IV criteria for bipolar disorder I, dementia, or a psychotic disorder other than psychotic disorder NOS
* IQ less than 70
* Chronic or serious physical health problem requiring hospitalization within the next year (e.g., cancer)
* Plans to move to a province other than Ontario or BC in the next 2 years.
D: Inclusion Criteria:

* 18 to 40 years old
* in or out-patient in one of the recruiting center
* men or women
* with a borderline personality disorder
* written informed consent

Exclusion Criteria:

* inferior to 18 or superior to 40 years old
* schizophrenia
* severe somatic disorder
* participation refusal
* participation to another interventional study

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Cognitive Group Treatment for Borderline Outpatients
Brief Summary: This study will expose patients to either a Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) to determine the more effective therapy for treating borderline personality disorder.


Options:
A: Inclusion Criteria:

1. Over 20 years old
2. Suffering from Axis I disorder
3. Had intent for suicide (confirmed more than 2 times)
4. Able to understand this study and provide informed consent
5. Able to have interview before trial registry and psycho education at hospital
6. Able to have interview for assessment at continuous follow-up care by case manager at the hospital

Exclusion Criteria:

1. Not suffering from Axis I disorder as a primary diagnosis
B: Inclusion Criteria:

* Borderline Personality Disorder
C: Inclusion Criteria:

* 18-65 years of age.
* Newly suicide attempt within one month of the inclusion date.
* A minimum of two characteristics in the DSM-IV Borderline Personality Disorder (BPD)
* Informed consent.

Exclusion Criteria:

* Severe depression.
* Bipolar disorder.
* Psychosis within the schizophrenic spectrum.
* Anorexia Nervosa.
* Substance abuse.
* Mental retardation.
* Dementia.
* Lack of informed consent
D: Inclusion Criteria:

* All students in term 3 of their medical and psychology study at the University of Oslo in the autumn of 2009, and spring of 2010.
* All students in term 3 of their medical and psychology study at the University of Tromso in the autumn of 2010, and autumn of 2011.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Relaxation Response, Somatic Style and Rheumatoid Arthritis
Brief Summary: This study will evaluate the relative effectiveness of Relaxation Response (RR) training for the treatment of rheumatoid arthritis (RA). The study will compare RR training to RR training with cognitive behavioral therapy and to a standard RA education program.


Options:
A: Inclusion Criteria:

1. Must be at least 19 yrs-old in order to consent to treatment.
2. Must have received at least one diagnosis consistent with chronic pain by a physician at one of the participating primary care clinics.
3. Must have experienced pain most days of the month for 3 months, and although pain may have more than one pain source, all pain must be non-malignant (e.g., not cancer- or HIV-related).
4. Must be able to speak and understand English.
5. Must have a telephone or other avenue of communication for contact regarding the study.

Exclusion Criteria:

1. Must not demonstrate significant cognitive impairment (based on results of a cognitive screener).
2. Must not have current, uncontrolled serious psychological disturbance (e.g., schizophrenia, bipolar disorder) or active substance abuse (based on responses to a structured diagnostic interview).
3. Must have minimal literacy skills (i.e., read at the 1st grade level).
4. Must have been stabilized for at least 4 weeks on current pain and psychotropic medication regimen to reduce potential confounds to treatment results.
5. Must not have a surgery scheduled for the intervention period (\~3 months).
6. Must neither be currently receiving a psychosocial treatment for pain (though they may be receiving psychotherapy for non-pain difficulties) nor be a participant in our previous treatment studies.
B: Inclusion Criteria:

* Patients with aged between 18-75 years-old who meet the diagnostic criteria of fibromyalgia established by the American College of Rheumatology (ACR)

Exclusion Criteria:

* Patients with a diagnosis not based on the ACR criteria
* Those with cognitive impairment or suffering from physical mental/psychiatric limitations
* Severe concurrent rheumatologic illness that impede participation in the study evaluations
* Those who are not expected to live at least 12 months
* Those without schooling.
C: Inclusion criteria

* RA as defined by the American College of Rheumatology
* English literacy and fluency

Exclusion criteria

* Major medical condition or illness which limits life expectancy or results in severe symptoms or functional disability (Duke Severity of Illness score \> 0.85)
* Fibromyalgia
* Received or currently receiving psychosocial treatment for RA
* Unavailability for Month 12 follow-up
D: Inclusion Criteria:

* Diagnosis of fibromyalgia
* Diagnosis of insomnia
* No sleep medications for at least 1 month, or stable on medications for at least 6 months
* Willing to be randomly assigned to a treatment
* Able to read and understand English

Exclusion Criteria:

* Sleep disorder other than insomnia
* Bipolar disorder
* Seizure disorder
* Severe untreated psychopathology
* Cognitive impairment

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Improving Antipsychotic Adherence Among Patients With Schizophrenia
Brief Summary: This is a randomized controlled trial examining the effectiveness of a pharmacy-based intervention designed to improve adherence with antipsychotic medications among patients with serious mental illness.


Options:
A: Inclusion Criteria:

* 65 years or older taking 4 or more chronic medications independently living

Exclusion Criteria:

* assisted living or nursing home residents presence of any serious medical condition for which 1-year survival was expected to be unlikely
B: Inclusion Criteria:

Patients must be adult veterans. Diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder. At least one active oral antipsychotic prescription. History of poor medication compliance.

Exclusion Criteria:

Have received depot antipsychotics in the last year. Have supervised medication administration. Have not attended a VA outpatient appointment in the past 6 months, and none are scheduled,. Are prescribed Clozapine. Have a fatal illness with a life expectancy less than 2 years.
C: Inclusion Criteria:

* 18 years of age or older
* self-identify as a person who has injected drugs in the last 12 months
* self-identify as a person who has had sex with at least one opposite sex partner within the last 3 months
* self-identify as HIV-seropositive
* be confirmed as HIV seropositive through oral fluid (saliva) HIV testing
* live in the geographic region under study,
* agree to have their blood drawn for CD4 count and viral load testing
* be willing to provide basic contact information (for follow-up)
* be able to communicate in English
* not have participated in the full-pilot of this intervention and not have enrolled previously in the present study.

Exclusion Criteria:

-
D: Inclusion Criteria:

* Individuals must qualify for HAART treatment by World Health Organization (WHO) criteria (Clinical Stage IV disease) and/or CD4 count of less than 200 and plan to start HAART therapy.
* Must be above 18 years of age
* Must be HAART treatment-naïve
* Must agree to home visits, and plan to live in Kenya for at least two years.

Exclusion Criteria:

* Individuals who are mentally incompetent or are pregnant are excluded from the study.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS
Brief Summary: The study will determine whether a daily vitamin and mineral supplement (a multivitamin including Vitamin A) will improve health when added to standard chemotherapy for tuberculosis. This study will compare the effectiveness of the multivitamin in HIV infected and HIV uninfected patients.


Options:
A: Inclusion Criteria:

* Sputum-confirmed pulmonary tuberculosis
* Resident of Zomba or Blantyre Districts, Malawi
* Willing to take tuberculosis chemotherapy as recommended by the National Tuberculosis Control Programme

Exclusion Criteria:

* Prior treatment for tuberculosis
B: Inclusion Criteria:

* New pulmonary (including pleural) tuberculosis with/without an extrapulmonary lesion in children age 6 months to 15 years

Exclusion Criteria:

* Weight for height \< 70 % of NCHS median (reason: zinc as per guidelines is given as standard point of care to all severely malnourished children)
* Bilateral pedal oedema
* Known HIV + ve
* Place of residence outside Delhi (including physicians discretion)
* History of previous ATT treatment or INH prophylaxis for more than 48 hours prior to enrollment
* Signs of upper airway obstruction, or an arterial oxygen saturation less than 92% in room air
* Signs of renal, hepatic, or cvs disease
* Unable to attend follow up session for reading of Mantoux tests
* Documented intake of zinc continuously for \> 2 weeks in the preceding 4 weeks at enrollment
* CNS, osteo-articular, pericardial, renal TB
* History of contact with a documented case of drug resistant TB
C: Inclusion Criteria:

* Informed and written consent to take part in the study
* Previously untreated and newly diagnosed smear positive Tb patients according to the WHO definitions

Exclusion Criteria:

* Hospitalization
* Pregnancy
* Known allergy against peanuts
* Chronic or acute disease other than tuberculosis/HIV
D: Inclusion Criteria:

* Adults \>15 years with sputum smear positive pulmonary TB
* New cases only
* Agree to continue treatment in Timika for the full six month course of treatment -Not pregnant
* Consent to enroll in the study.

Exclusion Criteria:

* hypercalcaemia (ionized calcium \>1.32 mmol/L) identified at baseline
* taking arginine or vitamin D

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: CBASP Augmentation for Treatment of Chronic Depression
Brief Summary: This 24-week study, with a 12-month follow up period, will compare the effectiveness of antidepressant medication alone to the combination of psychotherapy and antidepressant medication in patients with chronic depression.


Options:
A: * between the ages of 12 and 18 years 11 months
* currently in treatment for depression
* taking Prozac,Zoloft, Luvox, Lexapro, Celexa or Paxil (Oregon and Rhode Island sites only)
* still feeling depressed
B: Inclusion Criteria:

* all patients will meet criteria for recurrent major depression or dysthymia

Exclusion Criteria:

* bipolar disorder or psychotic disorder
C: Inclusion Criteria

* Major depressive episode
* Depressive symptoms \> 2 years without remission
* Hamilton Depression Scale (HAM-D) score \> 20
* Fluent in English

Exclusion Criteria

* Psychotic disorders, bipolar disorder, post traumatic stress disorder, obsessive compulsive disorder, or eating disorder
* Serious, unstable, or terminal medical condition
* Axis II diagnosis of antisocial, schizotypal, or severe borderline personality disorder
* Previous treatment with CBASP
* Previous ineffective treatment with 4 of the medication treatments used in the study
* Substance abuse
* Pregnancy
* Not willing to end other psychiatric treatment
D: Inclusion Criteria:

* Enrolled patient at Community Psychiatric Clinic (CPC), a large mental health center in urban Seattle, Washington;
* Between 18 and 65 years of age;
* Diagnosis of of methamphetamine, amphetamine(illegal), or cocaine dependence or abuse;
* CPC medical record diagnosis of schizophrenia, schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder
* Stimulant drug use one month before enrollment;
* Ability to understand written and spoken English;
* CPC clinical case manager must affirm the potential participant's ability to provide informed consent and clinical appropriateness (i.e., safety/severity of mental/substance/ physical health) to participate in the study.

Exclusion Criteria:

* Any medical/psychiatric condition, or severity of that condition, that, in the opinion of Dr. Ries, the PI, would compromise safe study participation
* Chart defined organic brain disorder or dementia;
* Current participation in a methadone maintenance program;
* Any other circumstances that in the PI's opinion precludes safe study participation.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Recurrence in Depression With Drugs and CT
Brief Summary: This study will determine whether the addition of Cognitive Therapy (CT) to antidepressant medication (ADM) enhances treatment for depression. This study will also test whether the addition of CT to ADM will prevent recurrences of depression after therapy is over.


Options:
A: Inclusion Criteria:Unipolar depression -

Exclusion Criteria:Psychosis, other psychiatric disorders, subclinical depression, suicidal ideation, learning disabilities

-
B: Inclusion Criteria:

* Primary diagnose of unipolar treatment resistant depression

Exclusion Criteria:

* Patients diagnose of: bipolar disorder, psychosis, high suicide risk, Intellectual disability, illicit drug dependence.
* Currently in or having received psychotherapy in the last 4 weeks
C: Inclusion Criteria:

* all patients will meet criteria for recurrent major depression or dysthymia

Exclusion Criteria:

* bipolar disorder or psychotic disorder
D: Inclusion Criteria:

* Recurrent or chronic major depressive disorder

Exclusion Criteria:

* Current diagnosis of psychotic affective disorder
* History of nonaffective psychotic disorder
* Substance dependence last three months requiring detox
* Schizotypal, antisocial, or borderline personality disorder

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Recurrence in Depression With Drugs and CT
Brief Summary: This study will determine whether the addition of Cognitive Therapy (CT) to antidepressant medication (ADM) enhances treatment for depression. This study will also test whether the addition of CT to ADM will prevent recurrences of depression after therapy is over.


Options:
A: Inclusion Criteria:

• Having received prescriptions for antidepressants in primary care for at least the past nine months

Exclusion Criteria:

* Current treatment by a psychiatrist
* Current diagnosis of substance use disorder
* Non-psychiatric indication for long-term antidepressant usage (i.e. neuropathic pain)
* Having participated in a mindfulness training (\> 3 sessions) within the last 5 years
* Inability to perform the assessments due to cognitive or language difficulties
* Younger than 18 years
B: Inclusion Criteria

* Clinical diagnosis for recurrent major depression

Exclusion Criteria

* The patient has failed on an adequate trial of fluoxetine, venlafaxine or venlafaxine ER during the current episode of major depression or the patient is treatment-resistant
* Known hypersensitivity to venlafaxine or fluoxetine
* History or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease, including history of seizure disorder
C: Inclusion Criteria:

* Principal (i.e., most severe or pressing problem) or co-principal current diagnosis of generalized anxiety disorder
* Pretreatment score of at least 17 on Hamilton Anxiety Rating Scale

Exclusion Criteria:

* Principal diagnosis other than GAD
* Clinically judged too psychiatrically unstable to participate in the study
* Cognitive impairment or dementia
* Alcohol or other substance use disorder within 6 months prior to study entry
* Lifetime diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder
* Serious, unstable, or terminal medical condition that would compromise study participation or preclude the use of escitalopram, as determined by a review of medical records
* Use of psychotropics that could not be safely tapered and discontinued for at least 2 weeks prior to study entry
* Use of depot neuroleptics within 6 weeks prior to study entry
* Unwillingness to terminate other forms of psychotherapy
* Already received adequate trial of escitalopram or CBT
D: Inclusion Criteria:

* Recurrent or chronic major depressive disorder

Exclusion Criteria:

* Current diagnosis of psychotic affective disorder
* History of nonaffective psychotic disorder
* Substance dependence last three months requiring detox
* Schizotypal, antisocial, or borderline personality disorder

Answer: D